B
BIORCHESTRA develops RNA-based therapeutics specifically designed to target and modify gene expression in neurodegenerative diseases. This approach aims to provide precise treatment options that address the underlying genetic factors contributing to conditions such as Alzheimer's and Parkinson's disease.
Updated 4 months ago
Funding
$59.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- BIORCHESTRA develops RNA-based therapeutics specifically designed to target and modify gene expression in neurodegenerative diseases. This approach aims to provide precise treatment options that address the underlying genetic factors contributing to conditions such as Alzheimer's and Parkinson's disease.